

A person in a wheelchair is sitting on a sandy beach, facing the camera with their arms raised in a gesture of joy or triumph. They are wearing sunglasses and a purple and black t-shirt. The background features a clear blue sky with scattered white clouds and a turquoise ocean. The wheelchair is positioned on a path of sand that has been marked with a grid pattern, possibly from a vehicle's tracks.

 ELIXIE | Nano-tech  
Cannabinoid  
Medicines

Elixie is a clinical-stage biotech company enhancing cannabinoids for symptomatic relief of neurological disorders



## Milestones

Bootstrapped a commercially viable product



Clinically validated technology



Broad exclusivity & IP protection



Approved for Phase 1 in humans



Key partners & collaborators



THE HEBREW UNIVERSITY OF JERUSALEM






# 30 countries

including the **US FDA**, have already **approved** cannabinoid-based drugs for treatment of MS-related **Spasticity** & rare forms of **Epilepsy**:

- **Dravet Syndrome**
- **Lennox Gastaut**
- **Tuberous Sclerosis**

# \$800 million


of revenue generated in **2022** for approved cannabinoid-based medicines





## PROBLEM

**Existing oral cannabinoid-based medicines have limited efficacy due to poor absorption**



### **Slow Onset**


45 - 90 min

### **Poor Bioavailability**

Low efficacy


### **Inconsistent Absorption**

Unpredictable response



SOLUTION

# NANOLIX™ drug-delivery technology maximizes efficacy by promoting high absorption of cannabinoids



**Instant Relief**  
5-15 min | 4x times faster


**Higher Bioavailability**  
Higher rate of efficacy

**Consistent Absorption**  
Predictable effect

THE TECH


# NANOLIX™

Self-Emulsifying Drug Delivery System (SNEDDS)




Granted : EU  
Pending : US | Canada | AUS

**Clinically Validated & Published**  
in 6 peer-reviewed scientific publications



## HOW IT WORKS

NANOLIX™ encapsulates hydrophobic drugs, creating nanoemulsions that improve the drug's absorption, stability, and solubility



NANOLIX™, our pre-concentrated composition of cannabinoids and Pro-Nano liposphere formulation

In contact with water, NANOLIX™ spheres are spontaneously formed around the cannabinoids

The cannabinoids are encapsulated in NANOLIX™ nanoparticles



# Product Development Pipeline

We enhance clinically proven API's with our Nanolix Technology to create highly soluble and affective cannabinoid-based medicines

Drug Candidate



Pre-Clinical

Phase 0

Phase 1

Phase 2 / 3

Marketing Approval

**Elidiol™**

NANOLIX™ + Cannabidiol  
(Purified CBD)

Anticonvulsant medication


Elinol is eligible for FDA orphan disease designation.

**Elinol™**

NANOLIX™ + Cannabinoids  
(THC+CBD)

Spasticity relief drug

Elidiol is eligible for FDA orphan disease designation.



# Regulatory Strategy - Orphan Drug Designation (ODD)

Orphan drugs are 56% more likely to be approved than other medicines

## Faster

We plan to target sub-populations (e.g. orphan diseases) to benefit a short time to market

## More Leverage

After approval for a lean indication, we will scale by targeting indications with comparable symptoms

## Better Benefits

ODD grants exclusive marketing rights for 7 years in the US and 10 years in the UK & EU + R&D costs benefits to cover rare disease treatment



# Elidiol™

Anticonvulsant medication

NANOLIX™ + Cannabidiol (Purified CBD)

Elidiol™ Oral emulsion is created to provide rapid symptomatic relief for rare epilepsy

# 50 million

People worldwide have epilepsy, making it one of the most common neurological diseases globally

# Elinol™

Spasticity relief drug

NANOLIX™ + Cannabinoids (THC+CBD)


Elinol™ Oral emulsion relieves spasticity for people with neurodegenerative diseases like multiple sclerosis (MS)

# 12 million

People suffer from **spasticity** - debilitating muscle contractions and stiffness due to neurological disorders

Elidiol™  
Elinol™

# Multi-Indication Strategy and Market Size



# Competitive landscape

	Elidiol™ & Elinol™	Sativex Epidiolex®	syqeair
Fast onset	✓		✓
High Bioavailability	✓		✓
Prolong effect	✓	✓	
Inclusive administration	✓	✓	




Syqe medical cannabis Inhaler enter a phase 3 study for FDA approval for neuropathic chronic pain



Epidiolex cannabinoid oral solution of GW pharmaceuticals is approved to treat rare forms of epilepsy

# Exit Point Opportunities





# THE TEAM

## Elixie's team boasts a proven record from top pharma & cannabis firms




**Yaron Shoob**  
CEO



**Dr. Mohammad Alyan**  
VP R&D & Engineering



**David Cohen**  
VP Product



**Andrew Rosen**  
VP Strategy



**M.Sc. Nir Treves**  
VP Clinical & Regulation



**M.Sc. Oded Lahmish**  
VP Tech Transfer



**Cheli Gonen**  
CRO



**Maya Hershko**  
Head of Regulatory Affairs



**Anna Permyakova**  
Research Assistant

## Scientific Advisory Board




**Prof Amnon Hoffman**  
Head of Biopharmaceutics of Drug Delivery Systems



**Prof Abraham J Domb**  
Chief Scientist



# Elixie seeks to raise a USD 2.5M SAFE Round





# Thank You

Yaron Shoob  
[yaron@elixie.com](mailto:yaron@elixie.com)

[www.elixie.com](http://www.elixie.com)

# Appendix



# Clinically Validated & Published in 6 peer-reviewed scientific publications

In human

## European Journal of Pharmaceutics & Biopharmaceutics

**Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers**

Dvora Izgelov<sup>1</sup>, Elyad Davidson<sup>2</sup>, Dinorah Barasch<sup>1</sup>,  
Aviva Regev<sup>3</sup>, Abraham J Domb<sup>1</sup>, Amnon Hoffman<sup>4</sup>

## Journal of Pharmaceutical Sciences

**PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers**

Jacob Atsmon<sup>1</sup>, Irina Cherniakov<sup>2</sup>, Dvora Izgelov<sup>2</sup>,  
Amnon Hoffman<sup>2</sup>, Abraham J Domb<sup>2</sup>, Lisa Deutsch<sup>3</sup>,  
Frederic Deutsch<sup>3</sup>, Daphna Heffetz<sup>4</sup>, Hagit Sacks<sup>4</sup>



## journal of controlled release

**Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration**

Irina Cherniakov<sup>1</sup>, Dvora Izgelov<sup>1</sup>, Dinorah Barasch<sup>1</sup>,  
Elyad Davidson<sup>2</sup>, Abraham J Domb<sup>1</sup>, Amnon Hoffman<sup>3</sup>

## INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pre-clinical - Animal model

**The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats**

Dvora Izgelov<sup>1</sup>, Eliyahu Shmoeli<sup>1</sup>, Abraham J Domb<sup>1</sup>,  
Amnon Hoffman<sup>2</sup>

## European Journal of Pharmaceutics & Biopharmaceutics

**The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration**

Dvora Izgelov<sup>1</sup>, Abraham J Domb<sup>1</sup>, Amnon Hoffman<sup>2</sup>

## European Journal of Pharmaceutics & Biopharmaceutics

**The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model**

Irina Cherniakov<sup>1</sup>, Dvora Izgelov<sup>1</sup>, Abraham J Domb<sup>1</sup>,  
Amnon Hoffman<sup>2</sup>